Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD01B
- Development stage
- Unknown
- Lead developer
- AC Immune
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PD01B is an AFFITOPE-based active immunotherapy candidate designed for the treatment of idiopathic Parkinson's disease. It consists of a short synthetic peptide (mimetope) that mimics the epitope of pathological alpha-synuclein (α-syn), coupled to a carrier protein and adsorbed to an aluminum hydroxide adjuvant. The vaccine is intended to stimulate the patient's immune system to produce specific antibodies that recognize and neutralize toxic α-synuclein aggregates, which are a hallmark of Parkinson's disease pathology. By promoting the clearance of these aggregates, PD01B aims to slow or stop the progression of neurodegeneration. Originally developed by AFFiRiS AG, the program was acquired by AC Immune S.A. in 2021. Clinical studies have demonstrated that PD01B is safe and well-tolerated, showing a sustained antibody response and potential clinical benefit in patients with early-stage Parkinson's disease.
- Other names
- AFFITOPE PD01B
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on PD01B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD01B.